Simulations Plus, Inc. (SLP) Income Statement Analysis

See more : Iniziative Bresciane S.p.A. (IB.MI) Income Statement Analysis – Financial Results

Complete financial analysis of Simulations Plus, Inc. (SLP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Simulations Plus, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.

You may be interested

Smart Wires Technology Ltd. (GOGRID-SDB.ST) Income Statement Analysis – Financial Results
Japan Post Holdings Co., Ltd. (JPHLF) Income Statement Analysis – Financial Results
Sintronic Technology Inc. (3536.TW) Income Statement Analysis – Financial Results
Lai Sun Development Company Limited (0488.HK) Income Statement Analysis – Financial Results
Clean Vision Corporation (CLNV) Income Statement Analysis – Financial Results

Simulations Plus, Inc. (SLP)

Industry: Medical - Healthcare Information Services

Sector: Healthcare

Website: https://www.simulations-plus.com

About Simulations Plus, Inc.

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996
Revenue	70.01M	59.58M	53.91M	46.47M	41.59M	33.97M	29.67M	24.14M	19.97M	18.31M	11.46M	10.07M	9.45M	11.72M	10.71M	9.14M	8.97M	8.86M	5.86M	4.75M	5.21M	5.48M	4.44M	3.91M	3.63M	3.47M	2.65M	2.49M	2.60M
Cost of Revenue	26.86M	11.63M	10.82M	10.60M	10.65M	9.03M	7.99M	6.31M	4.60M	4.32M	1.63M	1.65M	1.51M	2.88M	2.55M	2.32M	2.10M	2.08M	1.60M	1.51M	1.56M	1.54M	1.46M	1.56M	1.16M	1.65M	1.76M	1.25M	1.20M
Gross Profit	43.15M	47.95M	43.08M	35.87M	30.94M	24.94M	21.67M	17.83M	15.37M	14.00M	9.83M	8.42M	7.94M	8.84M	8.17M	6.82M	6.87M	6.78M	4.25M	3.24M	3.65M	3.95M	2.99M	2.35M	2.47M	1.82M	889.25K	1.24M	1.40M
Gross Profit Ratio	61.63%	80.48%	79.92%	77.19%	74.39%	73.43%	73.05%	73.87%	76.96%	76.43%	85.79%	83.65%	84.02%	75.44%	76.23%	74.61%	76.58%	76.49%	72.60%	68.27%	70.09%	71.96%	67.23%	60.08%	67.98%	52.45%	33.62%	49.77%	53.85%
Research & Development	5.75M	4.50M	3.21M	4.05M	2.97M	2.50M	1.79M	1.37M	1.45M	1.33M	952.77K	802.37K	947.56K	935.20K	969.87K	1.11M	990.49K	814.95K	445.25K	524.56K	515.02K	379.63K	382.14K	354.09K	299.88K	218.51K	390.45K	133.02K	100.00K
General & Administrative	22.35M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.56M	6.78M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	8.92M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	131.78K	38.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	31.27M	34.72M	24.97M	20.57M	16.36M	11.80M	9.58M	8.20M	6.69M	6.81M	4.44M	3.55M	3.38M	4.31M	4.33M	3.90M	3.70M	3.46M	2.97M	2.42M	2.51M	2.30M	2.11M	2.20M	2.14M	2.31M	2.68M	2.28M	1.20M
Other Expenses	0.00	2.97M	204.00K	0.00	14.30B	14.30B	8.14B	0.00	0.00	0.00	0.00	35.49K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	261.15K	0.00	0.00	0.00	100.00K
Operating Expenses	37.02M	39.22M	28.17M	24.61M	19.33M	14.30M	11.37M	9.57M	8.14M	8.14M	5.39M	4.35M	4.33M	5.24M	5.30M	5.01M	4.69M	4.27M	3.42M	2.95M	3.02M	2.68M	2.49M	2.55M	2.70M	2.53M	3.07M	2.41M	1.40M
Cost & Expenses	63.88M	50.85M	39.00M	35.21M	29.98M	23.32M	19.37M	15.87M	12.74M	12.46M	7.02M	6.00M	5.84M	8.12M	7.84M	7.33M	6.79M	6.36M	5.02M	4.46M	4.58M	4.22M	3.94M	4.12M	3.87M	4.18M	4.83M	3.66M	2.60M
Interest Income	4.38M	4.13M	717.00K	201.00K	29.47K	33.52K	27.12K	15.86K	18.01K	17.94K	31.44K	49.49K	89.27K	91.86K	101.55K	93.87K	0.00	0.00	0.00	0.00	0.00	233.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.00	0.00	717.00K	22.00K	0.00	109.08K	153.03K	38.19K	18.01K	17.94K	31.44K	49.49K	3.00	118.00	1.05K	93.87K	0.00	0.00	0.00	0.00	0.00	5.36K	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	5.67M	3.84M	3.57M	3.59M	2.96M	2.75M	2.72M	2.14M	1.93M	1.99M	1.04M	766.96K	715.44K	747.30K	682.94K	561.01K	543.42K	512.45K	363.18K	206.89K	223.98K	195.60K	191.83K	293.85K	261.15K	503.76K	632.09K	139.86K	-100.00K
EBITDA	11.80M	12.57M	18.49M	14.70M	11.85M	13.31M	11.72M	10.38M	9.17M	7.68M	5.48M	4.84M	4.67M	4.52M	3.79M	2.59M	2.72M	3.02M	1.20M	503.32K	850.21K	1.46M	691.94K	91.90K	24.49K	-205.28K	-1.70M	-1.03M	100.00K
EBITDA Ratio	16.85%	14.64%	27.66%	24.65%	28.50%	39.54%	43.98%	43.15%	45.95%	32.97%	38.36%	48.90%	46.74%	37.88%	34.12%	26.98%	29.43%	33.96%	19.85%	10.40%	16.33%	26.68%	15.57%	2.35%	0.60%	-10.25%	-61.53%	-30.75%	3.85%
Operating Income	6.13M	8.73M	11.34M	7.86M	8.89M	10.65M	10.30M	8.26M	7.23M	5.86M	4.44M	4.07M	3.61M	3.60M	2.87M	1.81M	2.18M	2.50M	833.14K	296.43K	626.23K	1.27M	500.11K	-201.95K	-236.66K	-709.05K	-2.18M	-1.17M	200.00K
Operating Income Ratio	8.76%	14.64%	21.03%	16.92%	21.38%	31.35%	34.71%	34.24%	36.21%	31.98%	38.74%	40.44%	38.23%	30.72%	26.80%	19.82%	24.29%	28.26%	14.23%	6.24%	12.03%	23.07%	11.25%	-5.16%	-6.52%	-20.45%	-82.58%	-46.90%	7.69%
Total Other Income/Expenses	6.28M	2.97M	204.00K	-168.00K	2.50M	-92.73K	-158.85K	-24.02K	4.59K	-163.60K	73.93K	184.41K	342.77K	169.40K	233.87K	214.83K	268.03K	121.69K	55.64K	51.69K	72.40K	-7.44K	-13.60K	-22.05K	-19.34K	133.98K	116.84K	-305.99K	0.00
Income Before Tax	12.41M	11.70M	15.12M	11.09M	11.39M	10.56M	10.14M	8.24M	7.24M	5.69M	4.51M	4.26M	3.95M	3.77M	3.10M	2.03M	2.45M	2.62M	888.78K	348.12K	698.63K	1.26M	486.52K	-224.00K	-256.00K	-575.07K	-2.07M	-1.48M	0.00
Income Before Tax Ratio	17.73%	19.63%	28.04%	23.86%	27.38%	31.08%	34.18%	34.14%	36.23%	31.08%	39.38%	42.27%	41.85%	32.17%	28.98%	22.17%	27.28%	29.63%	15.18%	7.32%	13.42%	22.94%	10.95%	-5.72%	-7.05%	-16.59%	-78.17%	-59.17%	0.00%
Income Tax Expense	2.46M	1.73M	2.63M	1.30M	2.05M	1.97M	1.20M	2.45M	2.29M	1.85M	1.49M	1.37M	1.14M	1.06M	948.43K	614.58K	720.61K	1.16M	212.90K	85.80K	-137.86K	-1.25M	1.60K	1.60K	1.60K	1.60K	1.60K	-38.80K	0.00
Net Income	9.95M	9.96M	12.48M	9.78M	9.33M	8.58M	8.93M	5.79M	4.95M	3.84M	3.03M	2.89M	3.03M	2.71M	2.16M	1.41M	1.73M	1.47M	675.88K	262.32K	836.49K	2.51M	484.92K	-225.60K	-257.60K	-576.67K	-2.07M	-1.44M	0.00
Net Income Ratio	14.22%	16.72%	23.16%	21.05%	22.44%	25.27%	30.12%	23.98%	24.79%	20.98%	26.40%	28.66%	32.05%	23.16%	20.13%	15.44%	19.24%	16.55%	11.54%	5.52%	16.07%	45.69%	10.91%	-5.76%	-7.10%	-16.63%	-78.23%	-57.62%	0.00%
EPS	0.50	0.50	0.62	0.49	0.52	0.49	0.52	0.34	0.29	0.23	0.19	0.18	0.19	0.17	0.14	0.09	0.11	0.10	0.05	0.02	0.06	0.18	0.04	-0.02	-0.02	-0.04	-0.62	-0.49	0.00
EPS Diluted	0.49	0.49	0.60	0.47	0.50	0.48	0.50	0.33	0.29	0.23	0.18	0.18	0.19	0.17	0.13	0.08	0.10	0.08	0.04	0.02	0.05	0.17	0.03	-0.02	-0.02	-0.04	-0.62	-0.49	0.00
Weighted Avg Shares Out	19.99M	20.08M	20.20M	20.05M	17.82M	17.49M	17.33M	17.24M	17.03M	16.86M	16.17M	16.00M	15.76M	15.54M	15.83M	16.13M	16.13M	15.28M	14.72M	14.44M	13.98M	13.64M	13.63M	13.58M	13.54M	13.51M	3.33M	2.94M	2.22M
Weighted Avg Shares Out (Dil)	20.30M	20.47M	20.75M	20.74M	18.54M	18.06M	17.86M	17.52M	17.21M	17.03M	16.41M	16.32M	16.15M	16.08M	16.51M	17.19M	18.14M	17.96M	16.29M	15.92M	15.58M	14.96M	14.10M	13.58M	13.54M	13.51M	3.33M	2.94M	2.22M

Wall Street Analysts Predict a 56.99% Upside in Simulations Plus (SLP): Here's What You Should Know

November 26, 2024zacks.com

The consensus price target hints at a 57% upside potential for Simulations Plus (SLP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an...

Simulations Plus (SLP) Stock Jumps 8.9%: Will It Continue to Soar?

November 22, 2024zacks.com

Simulations Plus (SLP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables

November 13, 2024businesswire.com

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, in partnership with the University of Connecticut, was awarded a new FDA grant to investigate additional LAI product technologies.

How Much Upside is Left in Simulations Plus (SLP)? Wall Street Analysts Think 77.52%

November 8, 2024zacks.com

The consensus price target hints at a 77.5% upside potential for Simulations Plus (SLP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an...

Simulations Plus to Participate in the Stephens Annual Investment Conference

November 6, 2024businesswire.com

LANCASTER, Calif.--(BUSINESS WIRE)--Shawn O'Connor, CEO, will participate in a fireside chat at the Stephens Annual Investment Conference on Wednesday, November 20, 2024 at 12:00pm ET.

Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations

October 30, 2024businesswire.com

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, with industry and academic partners, was awarded a new FDA grant to validate new methods for more efficient drug development.